All In Biotech

Drug Trial Radar · NCT07675226

Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions

An Open-label, Randomized, Fed, Single-dose, Oral Administration, 2-treatment, 2-period, Crossover Design, Phase 1 Clinical Trial to Evaluate the Bioequivalence of SKI-O-703 in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Oscotec Inc.Industry
Sponsor type
Industry
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, crossover Phase 1 study to evaluate the bioequivalence, pharmacokinetics, and safety of two oral SKI-O-703 drugs (test and reference) in healthy adults under fed conditions. Approximately 48 Korean and Caucasian participants will receive a single oral dose of the test drug and a single oral dose of the reference drug in a randomized sequence, separated by a washout period, with pharmacokinetic sampling and safety assessments performed throughout the study.

Conditions

  • Bioequivalence Study in Healthy Subjects
  • Immune Thrombocytopenia (ITP)
  • Rheumatoid Arthritis (RA)

Interventions

  • SKI-O-703 API in CapsulesDrug

    SKI-O-703 API in Capsules 100mg

  • SKI-O-703 Formulated Granules in CapsulesDrug

    SKI-O-703 Formulated Granules in Capsules 200mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To measure AUCt of SKI-O-592 (the free base of SKI-O-703)Time frame: Approximately 1 year
  2. To measure Cmax of SKI-O-592 (the free base of SKI-O-703)Time frame: Approximately 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Oscotec

    Seongnam-si, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.